Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services worldwide. The company reported a net loss of -$190,426,000.00 indicating challenges in its operations. Additionally, the net total of other income and expenses is $32,563,000.00 reflecting non-core financial activities. Despite this, the company reported an income before tax of -$189,731,000.00 showcasing its pre-tax profitability. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The EBITDA is -$148,078,000.00 a key indicator of the company's operational profitability. Natera offers a variety of diagnostic tests, including Panorama, a non-invasive prenatal test, and Vistara for single-gene mutations, among others. The company engages in direct sales as well as through a network of approximately 100 laboratory and distribution partners. Collaborations with organizations such as BGI Genomics Co., Ltd. for NGS-based genetic testing assays and Foundation Medicine, Inc. for personalized circulating tumor DNA monitoring assays further highlight its focus on enhancing diagnostic capabilities. Founded in 2003 and based in Austin, Texas, Natera was formerly known as Gene Security Network, Inc. before rebranding in 2012. The stock is reasonably priced at $137.65 appealing to a broad range of investors. It has a high average trading volume of 1,723,096.00 indicating strong liquidity within the market. With a mid-range market capitalization of $19,116,652,260.00 the company is a steady performer in its field. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it continues to expand its portfolio of genetic testing services. Natera's focus on improving health outcomes through advanced diagnostics positions it as a critical component of the evolving healthcare landscape.